Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis

References

• Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol. 2018;25(1):59–70.
   PubMed Web of Science ®Google Scholar
• Silva MVF, Loures CMG, Alves LC, et al. Alzheimer’s disease: risk factors and potentially protective measures. J Biomed Sci. 2019;26(1):33.
   PubMed Web of Science ®Google Scholar
• Tinelli C, Di Pino A, Ficulle E, et al. Hyperhomocysteinemia as a risk factor and potential nutraceutical target for certain pathologies. Front Nutr. 2019;6:49.
   PubMed Web of Science ®Google Scholar
• Tomaiuolo R, Ruocco A, Salapete C, et al. Activity of mannose-binding lectin in centenarians. Aging Cell. 2012;11(3):394–400.
   PubMed Web of Science ®Google Scholar
• Bellia C, Bivona G, Scazzone C, et al. Association between homocysteinemia and metabolic syndrome in patients with cardiovascular disease. Ther Clin Risk Manag. 2007;3(6):999–1001.
   PubMedGoogle Scholar
• Vivona N, Bivona G, Noto D, et al. C-reactive protein but not soluble CD40 ligand and homocysteine is associated to common atherosclerotic risk factors in a cohort of coronary artery disease patients. Clin Biochem. 2009;42(16–17):1713–1718.
   PubMed Web of Science ®Google Scholar
• Liu M, Sun A, Shin EL, et al. Expression of microsomal epoxide hydrolase is elevated in Alzheimer’s hippocampus and induced by exogenous beta-amyloid and trimethyl-tin. Eur J Neurosci. 2006;23(8):2027–2034.
   PubMed Web of Science ®Google Scholar
• Yamazaki Y, Zhao N, Caulfield TR, et al. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol. 2019;15(9):501–518.
   PubMed Web of Science ®Google Scholar
• Buscemi S, Di Pasquale V, Buscemi C, et al. Factors associated with mild cognitive impairment in a population-based cohort. Eur J Intern Med. 2017;43:e20–e21.
   PubMed Web of Science ®Google Scholar
• Wiltfang J, Lewczuk P, Riederer P, et al. Consensus paper of the WFSBP task force on biological markers of dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J Biol Psychiatry. 2005;6(2):69–84.
   PubMed Web of Science ®Google Scholar
• Blennow K, Zetterberg H. Biomarkers for Alzheimer’s disease: current status and prospects for the future. J Intern Med. 2018;284(6):643–663.
   PubMed Web of Science ®Google Scholar
• Dursun E, Gezen-Ak D. Vitamin D basis of Alzheimer’s disease: from genetics to biomarkers. Hormones (Athens). 2019;18(1):7–15.
   PubMedGoogle Scholar
• Bivona G, Gambino CM, Iacolino G, et al. Vitamin D and the nervous system. Neurol Res. 2019;41(9):827–835.
   PubMed Web of Science ®Google Scholar
• Bivona G, Agnello L, Bellia C, et al. Non-skeletal activities of vitamin D: from physiology to brain pathology. Medicina (Kaunas). 2019;55.
   Web of Science ®Google Scholar
• Bivona G, Bellia C, Lo Sasso B, et al. Short-term changes in Gal 3 circulating levels after acute myocardial infarction. Arch Med Res. 2016;47(7):521–525.
   PubMed Web of Science ®Google Scholar
• Bjerke M, Engelborghs S. Cerebrospinal fluid biomarkers for early and differential Alzheimer’s disease diagnosis. JAD. 2018;62(3):1199–1209.
   Web of Science ®Google Scholar
• Limongi F, Noale M, Bianchetti A, et al.; for the MCI Working Group. The instruments used by the Italian centres for cognitive disorders and dementia to diagnose mild cognitive impairment (MCI). Aging Clin Exp Res. 2019;31(1):101–107.
   PubMed Web of Science ®Google Scholar
• Alongi P, Sardina DS, Coppola R, et al. 18F-Florbetaben PET/CT to assess Alzheimer’s disease: a new analysis method for regional amyloid quantification. J Neuroimaging. 2019;29(3):383–393.
   PubMed Web of Science ®Google Scholar
• Blennow K, Hampel H, Weiner M, et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131–144.
   PubMed Web of Science ®Google Scholar
• Vogelgsang J, Vukovich R, Wedekind D, et al. Higher level of mismatch in APOEε4 carriers for amyloid-beta peptide Alzheimer’s disease biomarkers in cerebrospinal fluid. ASN Neuro. 2019;11:175909141984552–175909141984558.
   Web of Science ®Google Scholar
• Kollhoff AL, Howell JC, Hu WT. Automation vs. experience: measuring alzheimer’s beta-amyloid 1-42 peptide in the CSF. Front Aging Neurosci. 2018;10:253.
   PubMed Web of Science ®Google Scholar
• Mattsson N, Zegers I, Andreasson U, et al. Reference measurement procedures for Alzheimer’s disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42. Biomarkers Med. 2012;6(4):409–417.
   PubMed Web of Science ®Google Scholar
• Bayart JL, Hanseeuw B, Ivanoiu A, et al. Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ42 and T-Tau assays for Alzheimer’s disease diagnosis. J Neurol. 2019;266(9):2304–2311.
   PubMed Web of Science ®Google Scholar
• Alcolea D, Pegueroles J, Muñoz L, et al. Agreement of amyloid PET and CSF biomarkers for Alzheimer’s disease on Lumipulse. Ann Clin Transl Neurol. 2019;6(9):1815–1824.
   PubMed Web of Science ®Google Scholar
• McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–269.
   PubMed Web of Science ®Google Scholar
• Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–279.
   PubMed Web of Science ®Google Scholar
• del Campo M, Mollenhauer B, Bertolotto A, et al. Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update. Biomarkers Med. 2012;6(4):419–430.
   PubMed Web of Science ®Google Scholar
• Dumurgier J, Schraen S, Gabelle A, et al. Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimers Res Ther. 2015;7(1):30.
   PubMed Web of Science ®Google Scholar
• Janelidze S, Zetterberg H, Mattsson N, et al.; the Swedish BioFINDER study group. CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016;3(3):154–165.
   PubMed Web of Science ®Google Scholar
• Schindler SE, Gray JD, Gordon BA, et al. Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimers Dement. 2018;14(11):1460–1469.
   PubMed Web of Science ®Google Scholar
• Lewczuk P, Matzen A, Blennow K, et al. Cerebrospinal fluid Aβ42/40 corresponds better than Aβ42 to amyloid PET in Alzheimer’s disease. JAD. 2017;55(2):813–822.
   Web of Science ®Google Scholar
• Gervaise-Henry C, Watfa G, Albuisson E, et al. Cerebrospinal fluid Aβ42/Aβ40 as a means to limiting tube- and storage-dependent pre-analytical variability in clinical setting. JAD. 2017;57(2):437–445.
   Web of Science ®Google Scholar
• Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614–629.
   PubMed Web of Science ®Google Scholar
• Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998;55(7):937–945.
   PubMedGoogle Scholar
• Bjerke M, Andreasson U, Kuhlmann J, et al. Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements. Clin Chem Lab Med. 2016;54(7):1177–1191.
   PubMed Web of Science ®Google Scholar
• Kuhlmann J, Andreasson U, Pannee J, et al. CSF Aβ1-42 – an excellent but complicated Alzheimer’s biomarker – a route to standardisation. Clin Chim Acta. 2017;467:27–33.
   PubMed Web of Science ®Google Scholar
• Bivona G, Agnello L, Ciaccio M. Vitamin D and immunomodulation: is it time to change the reference values? Ann Clin Lab Sci. 2017;47(4):508–510.
   PubMed Web of Science ®Google Scholar
• Agnello L, Bellia C, Scazzone C, et al. Establishing the 99th percentile for high sensitivity cardiac troponin I in healthy blood donors from Southern Italy. Biochem Med (Zagreb). 2019;29(2):020901.
   PubMed Web of Science ®Google Scholar
• Agnello L, Bellia C, Lo Sasso B, et al. Establishing the upper reference limit of Galectin-3 in healthy blood donors. Biochem Med (Zagreb). 2017;27(3):030709.
   PubMed Web of Science ®Google Scholar
• Bivona G, Lo Sasso B, Iacolino G, et al. Standardized measurement of circulating vitamin D [25(OH)D] and its putative role as a serum biomarker in Alzheimer’s disease and Parkinson’s disease. Clin Chim Acta. 2019;497:82–87.
   PubMed Web of Science ®Google Scholar
• Vanderstichele H, Bibl M, Engelborghs S, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: a consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. Alzheimer’s Demen. 2012;8(1):65–73.
   PubMed Web of Science ®Google Scholar
• Engelborghs S, Niemantsverdriet E, Struyfs H, et al. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement (Amst). 2017; 18:111–126.
   PubMedGoogle Scholar
• Zecca C, Brescia V, Piccininni M, et al. Comparative evaluation of two immunoassays for cerebrospinal fluid β-Amyloid1-42 measurement. Clin Chim Acta. 2019;493:107–111.
   PubMed Web of Science ®Google Scholar
• Janelidze S, Pannee J, Mikulskis A, et al. Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment. JAMA Neurol. 2017;74(12):1492–1501.
   PubMed Web of Science ®Google Scholar
• Paciotti S, Sepe FN, Eusebi P, et al. Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer’s disease diagnosis. Clin Chim Acta. 2019;494:74–78.
   PubMed Web of Science ®Google Scholar